Newport Beach, Calif., February 21, 2013
– For the millions who suffer from Gastroesophageal Reflux Disease
(GERD), a study published today in the New England Journal of Medicine
(NEJM) provides clinical evidence of safety and effectiveness for a new,
FDA-approved medical device. Torax Medical’s LINX® Reflux Management
System was studied in a controlled, prospective, multicenter trial involving
14 U.S. and European medical centers as part of the FDA pre-market approval
process. The patients were evaluated before and after treatment to determine
the effect of the LINX System on their GERD using pre-defined success
criteria, which included reduction of esophageal acid, improvement in
quality of life and elimination of reflux medications.